All News

Findings from the phase 1/2 CA001-030 study indicate that BMS-986012 in combination with nivolumab is well tolerated among patients with small cell lung cancer.

Moxetumomab pasudotox-tdfk, approved as a treatment for relapsed/refractory hairy cell leukemia in 2018, will be withdrawn from the United States market in July 2023.

The FDA grants orphan drug designation to investigational G-quadruplex transcription inhibitor QN-302 for pancreatic cancer.

An expert from Rutgers Cancer Institute indicates that mosunetuzumab may limit unmet needs commonly associated with CAR T-cell therapy such as cost, tolerability, and access.

An expert from Natera shares multidisciplinary takeaways from the GALAXY cohort of the CIRCULATE-Japan study, assessing circulating tumor DNA as a prognostic biomarker for resectable colorectal cancer.

An expert from Natera indicates that post-operative ctDNA level may have strong prognostic and predictive value in patients with resectable colorectal cancer.

LP-284, which now has orphan drug designation from the FDA for mantle cell lymphoma, yielded positive preclinical data at the 2022 American Society of Hematology Annual Meeting and Exposition.

Yancey Warren, Jr, MD, MAT, and Lejla Hadzikadic-Gusic, MD, MSc, spoke with CancerNetwork® about their work investigating the use of integrative oncology services among young patients diagnosed with breast cancer.

Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota details the efficacy of breast-conserving surgery in patients with multiple ipsilateral breast cancer.

The FDA gave the dual epigenetic modulator JBI-802 an orphan drug designation to treat small cell lung cancer and acute myeloid leukemia.

An expert from Rutgers Cancer Institute reviews data that lead to the approval of mosunetuzumab for patients with relapsed/refractory follicular lymphoma.

Patients with HER2-positive breast cancer and triple-negative breast cancer may not require breast surgery if a pathological complete response can be identified using image-guided vacuum core biopsy following neoadjuvant systemic therapy.

Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota, details the multidisciplinary work that goes into delivering breast-conserving therapy for patients with multiple ipsilateral breast cancer.

OncobiotaLUNG, a novel liquid biopsy that detects lung cancer, now has a breakthrough device designation from the FDA.

The investigational drug CFI-402257 alone and in combination with fulvestrant received fast track designation from the FDA for patients with estrogen receptor–positive, HER2-negative advanced breast cancer.

During the 2022 Society for Urologic Oncology (SUO) Annual Meeting, an expert from the Baylor College of Medicine, discussed how perceptions around the use of testosterone therapy have evolved for patients with metastatic prostate cancer.

In a population of patients with patients with mantle cell lymphoma and follicular lymphoma, zandelisib plus zanubrutinib did not increase the rate or severity of class-related adverse effects.

Azeliragon was first evaluated in a group of patients with Alzheimer’s disease prior to being assessed in patients with glioblastoma, a fast-growing and aggressive brain tumor.

Adding the investigational oral drug BXCL701 to pembrolizumab appears effective in small cell neuroendocrine metastatic castration-resistant prostate cancer, a rare and aggressive disease.

Data from a meta-analysis suggest that single-fraction stereotactic ablative body radiotherapy could result in a lower incidence of local failure than multifractionated radiation in patients with renal cell carcinoma.

Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota discusses the incidence of complications and patient-reported outcomes associated with breast conservation therapy for multiple ipsilateral breast cancer.

Lenalidomide plus rituximab consolidation therapy prior to bendamustine/rituximab induction did not significantly improve progression-free survival in patients with mantle cell lymphoma in the phase 2 NCTN E1411 trial.

The National Medical Products Administration of China gives approval to mobocertinib for patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

The use of cobimetinib was effective in patients with Rosai-Dorfman disease, and responses were especially deep in those with KRAS or MEK alterations, according to findings from a recent retrospective study.

An expert from the Mayo Clinic notes that there’s also a great amount of interest in further optimizing the dose of radiation after mastectomy, especially in patients with breast cancer immediately following reconstruction.

A contingent of patients with a type of lung cancer and breast cancer continues to experience responses to treatment with zotatifin, according to updated study findings.

Patients with metastatic prostate cancer and dysphagia or difficulty swallowing may benefit from TAVT-45 compared with abiraterone acetate tablets.

A stool-based, non-invasive, at-home colorectal cancer and advanced adenoma test showed a strong ability to detect disease, according to updated trial results.

Findings from the phase 1b/2 NEXICART-1 study indicated that NXC-201 produced complete responses in 6 evaluable patients with relapsed or refractory AL amyloidosis.

Hypofractionated—large doses of radiation given over a shorter period of time than standard radiation—and conventional proton radiotherapy yielded comparable normal tissue sparing and complication rates postmastectomy in patients with breast cancer, according to findings from a recent study.